Zurcher Kantonalbank Zurich Cantonalbank lowered its holdings in Genomic Health, Inc. (NASDAQ:GHDX) by 24.9% during the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the medical research company’s stock after selling 491 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Genomic Health were worth $104,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Royce & Associates LP lifted its position in shares of Genomic Health by 22.8% in the 4th quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock worth $95,000 after acquiring an additional 273 shares during the period. Advisor Group Inc. lifted its position in shares of Genomic Health by 34.9% in the 4th quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock worth $129,000 after acquiring an additional 516 shares during the period. Quantamental Technologies LLC bought a new stake in shares of Genomic Health in the 4th quarter worth approximately $180,000. Amalgamated Bank bought a new stake in shares of Genomic Health in the 4th quarter worth approximately $203,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Genomic Health in the 4th quarter worth approximately $213,000. 96.21% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Genomic Health stock traded up $0.88 during midday trading on Friday, hitting $54.07. 754,652 shares of the company were exchanged, compared to its average volume of 479,430. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.67 and a quick ratio of 5.67. The company has a market capitalization of $2.00 billion, a PE ratio of 51.50 and a beta of 0.88. Genomic Health, Inc. has a 52 week low of $36.94 and a 52 week high of $92.18.
Genomic Health (NASDAQ:GHDX) last posted its earnings results on Tuesday, May 7th. The medical research company reported $0.34 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.05. The business had revenue of $108.80 million during the quarter, compared to the consensus estimate of $106.75 million. Genomic Health had a return on equity of 18.70% and a net margin of 10.35%. Genomic Health’s revenue was up 17.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.11) EPS. Equities analysts anticipate that Genomic Health, Inc. will post 1.46 earnings per share for the current fiscal year.
A number of analysts have commented on GHDX shares. ValuEngine downgraded Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, March 5th. BidaskClub downgraded Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 28th. Canaccord Genuity reiterated a “buy” rating and issued a $85.00 price objective (down previously from $95.00) on shares of Genomic Health in a research report on Wednesday, May 8th. Zacks Investment Research downgraded Genomic Health from a “buy” rating to a “hold” rating in a research report on Tuesday, April 23rd. Finally, Piper Jaffray Companies raised their price objective on Genomic Health to $86.00 and gave the stock a “neutral” rating in a research report on Thursday, February 21st. Ten equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $63.71.
In related news, Director Bros. Advisors Lp Baker sold 600 shares of the firm’s stock in a transaction that occurred on Thursday, February 28th. The stock was sold at an average price of $76.20, for a total transaction of $45,720.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Henry J. Fuchs sold 3,521 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $79.02, for a total value of $278,229.42. Following the transaction, the director now owns 26,332 shares of the company’s stock, valued at approximately $2,080,754.64. The disclosure for this sale can be found here. Insiders have sold a total of 1,421,962 shares of company stock valued at $101,721,648 in the last 90 days. 31.30% of the stock is owned by corporate insiders.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Featured Article: 52-Week High/Low
Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.